angiotensin II receptor antagonist


angiotensin II receptor antagonist

Any of a family of agents (e.g., losartan and valsartan) that block the binding of angiotensin II (A-II) to their cognate cell receptors—AT1, AT2 and others. First-generation ARAs included the sartan family of agents, which only block AT1, interacting with the amino acids in the transmembrane domains to block the binding of A-II to AT1.
ARAs are an alternative to ACEI therapy in patients with CHF; unlike ACEIs, ARAs do not interfere with bradykinin and prostaglandin metabolism, interference of which has been linked to some of the adverse effects of ACEI therapy, particularly to cough and angioedema.

angiotensin II receptor antagonist

Pharmacology Any of a family of agents-eg losartan and valsartan, which block the binding of angiotensin II–A-II to its cognate cell membrane receptors–AT1, AT2, and others; 1st generation ARAs included the sartan family of agents, which only block AT1, interacting with the amino acids in the transmembrane domains, blocking the binding of A-II to AT1; an alternative to ACEI therapy for Pts with CHF; unlike ACEIs, ARAs do not interfere with bradykinin and prostaglandin metabolism, interference which has been linked to some of the adverse effects of ACEI therapy, particularly to cough and angioedema.